Paclitaxel will be given intravenously at a dose of 175 mg/m^2 on an outpatient basis over 3 hours on Day 1 of each 21-day cycle
Carboplatin will be given intravenously at a dose of AUC 6 over 30 minutes on Day 1 of each cycle of chemotherapy
AVB-S6-500 will be given at doses based on the dose escalation schema
The investigators will continue dosing AVB-S6-500 until 1 week prior to surgery and continuing after surgery. Maintenance dosing q2 weeks will begin with Cycle 7A/7B and be given every 2 weeks for 12 months through Cycle 19 (total of 13 maintenance cycles).

Epithelial Ovarian Cancer

Primary Peritoneal Carcinoma

Fallopian Tube Cancer

AVB-S6-500 is supplied by Aravive Biologics

AVB-S6-500

Paclitaxel

Carboplatin

-For patients scheduled to undergo a diagnostic laparoscopy for tissue diagnosis prior to neoadjuvant chemotherapy, a tissue biopsy section from the ovary or an intra-abdominal implant will be performed

Tissue from Diagnostic Laparoscopy

-Standard of care procedure but research specimens will be collected

Tissue from Core biopsy

Standard of Care
Research tissue samples will be collected

Interval Debulking

-Before initiation of neoadjuvant chemotherapy and at the time of interval debulking surgery either pre-operatively, intraoperatively, or post-operatively.

Peripheral blood

-A total of 25-100ml of ascites will be collected prior to chemotherapy treatment, if available.

Ascites collection

Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Washington University School of Medicine

University of Oklahoma

Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

Phase IB Study of Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

The study will employ the Bayesian optimal interval design (BOIN) to find the MTD.
Select as the MTD the dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate. If there are ties, select the higher dose level when the isotonic estimate is lower than the target toxicity rate and select the lower dose level when the isotonic estimate is greater than or equal to the target toxicity rate.

-Hematologic DLT any of the following that occur during the 1st cycle (C) that are possibly (pos), probably (prob), or definitely (def) related to the study treatment:
Grade (Gr.) 4 neutropenia or thrombocytopenia > 7 day
Febrile neutropenia w/ temp > 38.5 °C
Gr. 4 anemia or Gr. 4 thrombocytopenia which requires transfusion therapy on more than 2 occasions in 7 days
Gr. thrombocytopenia w/ bleeding
Non-hematologic DLT is any pos, prob, or def related Gr. 3 or grade 4 non-hematologic toxicity that occurs during C1 with the following exceptions:
Gr. 3/4 nausea/vomiting/anorexia that returns to Gr. 1 prior to the start of C2
Gr. 3 nausea/vomiting or diarrhea < 72 hours with adequate antiemetic and other supportive care starting with C2
Gr. 3 triglycerides will only be considered a DLT for patients who have grade 3 in spite of appropriate lipid lowering drug therapy
Gr. 3 rash (patients who have received 2 weeks of supportive care treatment w/ no improvement)

-cOR = clinical response seen at the time of surgery with no visible disease

-pCR = pathological response seen by the pathology at the time of surgery with treatment effect and no disease seen microscopically

PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.
Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).

-OS is defined as the time from the date of treatment to the date of death, censored at the last follow-up otherwise.

Aravive, Inc.

Ovarian Cancer

Chemotherapeutic Toxicity

500mg,po, adjusted to 250mg if cannot tolerate, 3 weeks a cycle for a total of 6 cycles

Apatinib

Taxanes are paclitaxel or docetaxel, and platinum is carboplatin or cisplatin. Docetaxel injection dose size of 60-75mg / m2, infusion time of 1 hour; paclitaxel injection dose size 135-175mg / m2, infusion time> 3 hours; injection of carboplatin dose according to the standard formula Calculated, AUC = 4-5, continued intravenous infusion the next day; cisplatin injection dose size of 75-100mg / m2.

Taxus + platinum

Zhang xuan

A Study of Apatinib Treatment in for Advanced Ovarian Cancer

A Study of Apatinib in Combination With Chemotherapy Versus Chemotherapy Alone for Advanced Ovarian Cancer

he length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.

Cancer antigen 125 (CA-125) is a protein found on the surface of many ovarian cancer cells. It also can be found in other cancers and in small amounts in normal tissue. A CA-125 test measures the amount of this protein in the blood.

Zhang Xuan

M.D., head of the department of the obstetrics and gynecology

The People's Hospital of Leshan

Jiangsu HengRui Medicine Co., Ltd.

Vandetanib Treatment

Sex: Female, Male

Region of Enrollment

Defined as complete response (CR), partial response (PR), or disease stabilization lasting 6 months or longer per RECIST criteria. CR-total disappearance of all evaluable disease. PR->30% reduction in the sum of the longest diameters (LD) of target lesions. Stable disease (SD) is <30% decrease and <20% increase in the sum of the LD of all target lesions. See the protocol Link module for full RECIST criteria.

Number of Participants With Clinical Efficacy

Here are the total # of participants with adverse events. For the detailed list of adverse events, see the adverse event module.

The Number of Participants With Adverse Events

Overall Study

Elise C. Kohn, M.D.

Ovarian Neoplasms

Fallopian Tube Neoplasms

Peritoneal Neoplasms

Vandetanib

National Institutes of Health Clinical Center, 9000 Rockville Pike

Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase II Study of Clinical Activity and Proteomic Pathway Profiling of the Vascular Endothelial Growth Factor 2 (VEGFR2) Inhibitor, ZD6474 (Vandetanib) in Women With Relapsed or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

CP-547,632

To obtain contact information for a study center near you, click here.

Pfizer Investigational Site

Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer

A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Recurrent Or Persistent Small-Volume Epithelial Ovarian Cancer, Primary Peritoneal Serous Cancer, Or Fallopian Tube Cancer

fallopian tube neoplasms/tyrosine

Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

A Study of Apatinib Treatment in for Advanced Ovarian Cancer

Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم